List view / Grid view

metastatic castration-resistant prostate cancer (CRPC)

 

article

Solving the taxing problems of taxanes?

4 November 2022 | By

Could the new wave of taxane chemotherapies succeed where traditional chemotherapies have failed? Colin Freund, Chief Executive Officer of Modra Pharmaceuticals, reveals the benefits of this emerging generation of anticancer treatment.